Influence of Bosentan on the Pharmacokinetics of Nintedanib
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT02667704
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Biberach, Germany
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT02668393
- Locations
- 🇫🇷
HOP d'Angers, Angers, France
🇫🇷HOP Jean Minjoz, Besançon, France
🇩🇪Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, Germany
Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Dexa Medica Group
- Target Recruit Count
- 23
- Registration Number
- NCT02660060
- Locations
- 🇮🇩
PT Equilab International, Jakarta, Indonesia
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 57
- Registration Number
- NCT02657408
- Locations
- 🇩🇪
Fraunhofer ITEM, Hannover, Germany
Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT02652416
- Locations
- 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan
Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 120
- Registration Number
- NCT02642614
- Locations
- 🇩🇪
Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, Germany
🇩🇪Fraunhofer ITEM, Hannover, Germany
🇸🇪Skånes universitetssjukhus, Lund, Lund, Sweden
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 430
- Registration Number
- NCT02640612
- Locations
- 🇺🇸
Accurate Clinical Research, Inc., Lincoln, Nebraska, United States
🇵🇱Medical Centre Pratia Warszawa, Warszawa, Poland
🇺🇦M.V. Sklifosovskyi Poltava RCH, Poltava, Poltava, Ukraine
Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: BI 695501 AutoinjectorDrug: BI 695501 Prefilled syringe
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 77
- Registration Number
- NCT02636907
- Locations
- 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
🇵🇱Wojewodzki Szpital Zespolony w Elblagu, Elblag, Poland
🇵🇱Medica Pro Familia Spolka Akcyjna, Oddzial w Gdyni, Gdynia, Poland
Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02635750
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Obesity
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31
- Registration Number
- NCT02632747
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada